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Abstract: The abnormal aggregation of amyloid β (Aβ) and its subsequent intra- and 
extracellular accumulation constitute the disease-causing cascade of Alzheimer’s disease (AD). 
The detection of Aβ aggregates and senile plaque formation, however, is nearly impossible 
during early pathogenesis, and the absence of a convenient screen to validate the activity of 
Aβ aggregation regulators impedes the development of promising drug targets and diagnostic 
biomarkers for AD. Here, we conjugated amyloid β42 (Aβ42) peptide to gold nanoparticles 
(AuNPs) to visualize Aβ42 aggregation via Aβ42 aggregation-induced AuNP precipitation. 
AuNP–Aβ42 precipitate was quantified by optical density measurements of supernatants and 
thioflavin T binding assay. Transmission electron microscopy (TEM) analysis also showed 
reduced interparticle distance of AuNPs and confirmed the Aβ42 aggregation-induced AuNP 
precipitation. Transthyretin, a widely known Aβ aggregation inhibitor, limited AuNP–Aβ42 
precipitation by preventing Aβ42 aggregation. Finally, according to TEM analysis, Aβ42-
conjugated AuNPs treated with blood-driven serum revealed the differentiated aggregation 
patterns between normal and AD. These findings may open a scientific breakthrough in finding 
a possible diagnostic and prognostic tool for neurodegenerative diseases involving abnormal 
protein aggregation as their key pathogenesis processes.
Keywords: transthyretin, Alzheimer’s disease, diagnosis, amyloid β aggregation, gold 
nanoparticle
Introduction
Abnormal protein aggregation is often the pivotal step in the disease-generating 
and propagating cascade of neurodegenerative diseases, including Alzheimer’s, 
Parkinson’s, and Huntington’s diseases.1–3 In particular, Alzheimer’s disease (AD) is 
the most common neurodegenerative disease, and the atypical polymerization and 
aggregation of amyloid β (Aβ) peptide in neuronal inclusions and plaques have long 
been considered the hallmark of AD pathology.3–5 The oligomeric form and senile 
plaques of Aβ peptide that result from aggregation are the chief causes of neuronal 
dysfunction, degeneration, toxicity, and, ultimately, brain malfunction, leading to 
malignant impairments in learning and memory in AD.1,3,6,7
The cleavage of amyloid precursor protein (APP) generates several Aβ species, 
predominantly Aβ40 and small fragments of Aβ42. Aβ42 clusters more rapidly than 
the former in a concentration- and temperature-dependent manner and is prone to link 
to intra- and extracellular deposits of Aβ aggregates, which are closely associated with 
the initiation of AD pathogenesis.2,4 Specifically, recent studies have demonstrated that 
the oligomeric form is more closely linked to neurotoxicity and memory impairment International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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compared with the fibrillated form in senile plaques, 
which appears to be a secondary phenomenon following 
initiation.1,3,6
In addition to the developing amyloid hypothesis in AD, 
attention on Aβ aggregation inhibitors has increased in an 
attempt to impede aggregation. Evidence suggests that there 
is an endogenous inhibitor of Aβ aggregation.8,9 Transtyretin 
(TTR), originally known as thyroid hormone T4 and retinol 
transporter, acts as an Aβ aggregation inhibitor by binding 
and sequestering Aβ, thereby preventing amyloidogenesis.9,10 
TTR is a homotetrameric 55-kDa protein that is produced in 
the liver and choroid plexus and exists in cerebrospinal fluid 
(CSF) and blood. Increased TTR levels in the Tg2576 mouse, 
an APP-overexpressing AD animal model, prevented Aβ 
plaque formation and neuronal loss for 12 months, despite 
rising Aβ levels in the brain.10,11 Moreover, decreased TTR 
concentrations in CSF in human AD patients caused unbound 
Aβ peptide to aggregate with Aβ oligomers and plaques to 
form, leading to neurotoxicity and synaptic dysfunction.12 
Based on these data, TTR is a potent Aβ aggregation inhibitor 
and regulates AD pathogenesis.9,12
The combination of biomedical science and nanotechnology 
has launched a new era in medicine, particularly with regard to 
inventing and applying new treatments and diagnostic devices. 
Gold nanoparticles (AuNPs) have attracted much attention due 
to their unique properties, including amenability to particle 
size control, chemical composition, and surface modifications. 
Moreover, surface plasmon resonance (SPR) is a distinct 
characteristic that induces the intense red color of AuNP col-
loidal solutions and can be modulated based on concentration, 
particle size, and interparticle distance.13,14 For 50-nm diameter 
AuNPs, the SPR peak develops at 520 nm, which causes the 
red color of this colloidal solution.13 Further, the enormous 
surface area of nanoparticles enhances protein fibrillation by 
reducing the lag time of nucleation.15 Much effort has been 
made to use AuNPs whose surfaces have been modified with 
nucleotides, antibodies, and drugs to sense and sequence DNA, 
target cancer, and mediate protein disaggregation.14,16,17
Here, we induced and visualized neuropathogenic Aβ42 
aggregation optically by precipitating Aβ42-conjugated 
AuNPs. The optical density of free AuNPs (Aβ42-conjugated 
particles that did not precipitate) in supernatant was mea-
sured to quantify the precipitation, and thioflavin T (ThT) 
  binding assay verified and quantified Aβ aggregation-induced 
AuNP precipitation. AuNP–Aβ42 precipitation occurred in a 
conjugated Aβ42 concentration-dependent manner and was 
blocked by TTR, a well known Aβ aggregation inhibitor. 
Moreover, this system differentiated particle distances and 
aggregation patterns in blood-derived samples from normal 
and AD patients.
Materials and methods
Preparation of AuNPs and conjugation  
of Aβ42 to AuNPs
Streptavidin-conjugated AuNPs (40 nm, optical density 
at 520 nm = 10.3, BBInternational, Cardiff, UK) were 
  centrifuged and washed with distilled water 3 times and sus-
pended in phosphate buffer solution (PBS) (pH = 7.2). The 
  streptavidin–AuNP solution was combined with biotin-tagged 
Aβ42 (biotin–Aβ42 [H-5642.0500, Bachem, Torrance, CA, 
USA] dissolved in dimethyl sulfoxide [DMSO]) to a desig-
nated concentration and mixed thoroughly. The AuNP–Aβ42 
  solution was incubated for 48 hours at room temperature (RT) 
to induce aggregation.
Dot blot analysis to confirm  
Aβ42 conjugation to AuNP
Control (AuNPs without Aβ42) and AuNP–Aβ42 were 
loaded onto a nitrocellulose membrane (Protran®, Schleicher 
& Schuell, Keene, NH, USA) immediately after biotin–
streptavidin reaction and the extensive washes with distilled 
water. Anti-Aβ42 (epitope: Aβ17–24 monoclonal antibody 
4G8 [SIG-39220, Covance, Princeton, NJ, USA]) was used 
to detect Aβ42 on the surface of AuNPs, visualized using 
horseradish peroxidase-conjugated secondary antibody 
(HRP-anti-mouse IgG, Pierce, Rockford, IL, USA) in an 
enhanced chemiluminescence reaction (GE Healthcare, 
Piscataway, NJ, USA). Images were taken on Las-3000 (Fuji 
Film, Tokyo, Japan).
Optical density measurements  
and ThT binding assay
The optical density of the supernatant was measured at 
520 nm on a spectrophotometer (ND-1000, NanoDrop, 
Wilmington, DE, USA). For the ThT binding assay, 20 µL 
of sample was mixed with 150 µL of 5 µmol/L Thioflavin T 
solution in 50 mmol/L glycine buffer, and the fluorescence 
was measured within 15 minutes (Infinite M200, TECAN, 
Switzerland, excitation 437, emission 485 nm).
Blood-derived serum preparation
Blood (3 mL) from normal and AD patients was provided 
by Samsung Medical Center with approval from the local 
ethical review board; informed consent was obtained from 
all subjects. Vaccutainers (Vacuette [#450076, Greimer 
Bio-One, Monroe, NC, USA]) and SST tubes (SSTTMII International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Advance [#368972, Becton, Dickinson and Company, 
Franklin, NJ, USA]) were used to collect blood. Inside the 
SST tube, serum was separated by serum separation gel, and 
the upper serum layer was drawn and stored at -80°C.
Preparation and quantification  
of human serum TTr level
TTR was purchased from Sigma-Aldrich (St Louis, MO, 
USA), suspended and diluted in PBS (pH = 7.2), and incu-
bated with AuNP–Aβ42 solution for 48 hours at RT. Human 
TTR levels in serum were measured using a human prealbu-
min detection enzyme-linked-immunosorbent serologic assay 
(ELISA) kit (Standard Diagnostic, Inc., Kyunggi-do, Korea) 
according to the manufacturer’s guidelines. In brief, human 
sera were diluted with sample diluents 1:4000 (working on 
ice), loaded onto plates coated with human TTR-specific 
antibody (DAKO, Glostrup, Denmark) and incubated for 
30 minutes at 37°C. They were then washed five times 
and incubated with HRP-conjugated human TTR-specific 
antibody (Standard Diagnostic, Inc., Kyunggi-do, Korea) for 
30 minutes at 37°C. After being washed a further five times, 
stabilized TMB (3,3′,5,5′-tetramethylbenzidine) solution 
was added for 10 minutes at RT, and then stop solution was 
added. Absorbance at 450 nm was read using a plate reader 
(POWER-XS, BIO-TEK, Vinooski, VT, USA).
TeM analysis
AuNP–Aβ42 was prepared as described above; 1 drop 
(10 µL) of solution was mounted on a carbon-coated grid 
(200 mesh, Electron Microscopy Science, PA, USA). 
Two hours after filtering and drying at RT, TEM images were 
taken and analyzed on a JEM-1400 (Jeol, Tokyo, Japan).
statistical analysis
All data were expressed as mean ± SEM (standard error of 
the mean) or fold-change of the mean compared with con-
trol. Student t-test was used for two-group comparisons, and 
analysis of variance, followed by Tukey-Kramer multiple 
comparison test, was used to compare three or more groups. 
Significance was designated as P-value , 0.05.
Results
conjugation of Aβ peptide to AuNP  
and visualization of Aβ aggregation-
induced AuNP precipitation
In this initial step, we hypothesized that it would be possible 
to visualize protein aggregation if we conjugated Aβ peptides 
to the surface of nanoparticles that had distinct colors or 
characteristics (Figure 1). AuNPs in a colloidal solution have 
a unique red color due to SPR; the color is altered by changes 
in particle size, distance, and concentration.18 Aβ42 peptide 
was conjugated to AuNP (40 nm) by streptavidin–biotin 
reaction and then incubated for 48 hours at RT for inducing 
Aβ42 aggregation. The AuNP control was added to an equal 
amount of DMSO vehicle. Aβ42 conjugation to the AuNP 
was confirmed by dot blot analysis (Figure 2A). The AuNP 
control (without Aβ42 conjugation) failed to generate a 
signal, whereas AuNP–Aβ42 elicited a robust positive signal 
from anti-Aβ42.
Incubation at RT for 48 hours induced a visible purple pre-
cipitate and a clear supernatant in the AuNP–Aβ42 solution 
but not for unconjugated AuNP (Figure 2B). AuNPs had 
a distinct red color in colloidal solution, and AuNP–Aβ42 
precipitation was observed, as was a clearer supernatant than 
the AuNP control, due to the decreased concentration of free 
AuNPs. Changes in interparticle distance in AuNPs in the 
precipitate caused the color to change from red to purple 
and induced a thin, tightly packed layer of precipitate on 
the bottom of the tube.
The optical density of the supernatant at 520 nm (the 
property of AuNP that confers their red color) was mea-
sured and compared as a quantitative indicator of the 
amount of AuNP–Aβ42 precipitation. The supernatant of 
the AuNP–Aβ42 solution had a lower optical density than 
the unconjugated AuNP control (P , 0.0001) (Figure 2C), 
due to the AuNP–Aβ42 precipitate. By ThT binding assay, 
β-sheet-enriched Aβ42 aggregates were detected in the 
AuNP–Aβ42 precipitate, demonstrating that precipitation 
resulted from Aβ42 aggregation (P , 0.005) (Figure 2D); 
the ThT binding assay is routinely and frequently used to 
measure and quantify Aβ42 aggregation.19 AuNP–Aβ42 
precipitation caused a 238% increase in ThT values com-
pared with the AuNP control. A time-dependent increase of 
aggregation and precipitation of AuNP–Aβ42 was investi-
gated, and 48-hour incubation was the time point at which to 
maximize the reaction (Supplementary Figure 1).
Aβ42 concentration-dependent  
increase in AuNP–Aβ42 precipitation
We determined whether the amount of AuNP–Aβ42 precipitation 
was proportional to the concentration of Aβ42 that was conju-
gated to AuNPs. Biotin–Aβ42, at concentrations ranging from 
0 to 300 µmol/L, was conjugated to AuNPs and incubated for 
48 hours to induce precipitation. Based on the optical density and 
ThT binding assay results, AuNP–Aβ42 precipitation and Aβ42 International Journal of Nanomedicine 2011:6
+
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Figure 1 schematic of sequence of Aβ42 conjugation to AuNP surface via biotin–streptavidin interaction and formation of AuNP–Aβ42 precipitate by Aβ42 aggregation. 
Abbreviations: Aβ, amyloid β; Aβ42, amyloid β42; AuNP, gold nanoparticle.
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aggregation increased in an Aβ42 concentration-  dependent 
manner (Figure 3). AuNP–Aβ42 precipitation was visible 
between 10 and 50 µmol/L Aβ42, consistent with the results of 
the optical density and ThT binding assays, which demonstrated 
lower optical density and increased ThT binding, respectively, 
at 50 µmol/L.
Thus, the simultaneous changes in visual precipitation, 
optical density, and ThT binding at 50 µmol/L Aβ42   suggest 
that AuNP–Aβ42 precipitation is caused by Aβ42   aggregation. 
Above 50 µmol/L, the optical density pattern reversed, despite 
the increase in ThT binding (100, 300 µmol/L). We speculated 
that residual-free   biotin–Aβ42 in the solution incorporated into 
AuNP–Aβ42 precipitates during aggregation and expanded 
the interparticle distance, exceeding that in AuNP–Aβ42 
that did not contain extra biotin–Aβ42 (50 µmol/L) but 
remaining shorter than in the AuNP control. The appearance 
of AuNP–Aβ42 precipitates in 300 µmol/L biotin–Aβ42 in 
Figure 3A supports this model, because its aggregation pat-
tern differed compared with 50 µmol/L, developing a dark 
purple, cloudy, and   floating precipitate rather than a tight, thin 
layer. We believe that these floating AuNP–Aβ42 aggregate 
particles influenced the optical density measurements and 
increased the optical density; thus, the optimal biotin–Aβ42 
concentration for AuNP conjugation was 10–50 µmol/L, and 
we used this range for the remaining experiments, unless 
noted otherwise.
Inhibition of AuNP–Aβ42 precipitation 
by cotreatment with the Aβ aggregation 
inhibitor TTr
Because Aβ42 aggregation led to AuNP–Aβ42 precipitation, 
we examined whether we could use this system to evaluate the 
activity of an Aβ42 aggregation inhibitor. Aβ42 aggregation 
inhibitors prevent and alleviate Aβ42 aggregation, regulating 
AD pathogenesis.8,12 Based on increased Aβ deposits due to 
TTR mutation or deficiency, TTR is considered an Aβ aggre-
gation inhibitor and governs AD pathogenesis.11,20 We incu-
bated AuNP–Aβ42 with or without TTR (3 µmol/L, Sigma) 
for 48 hours and observed that TTR inhibited AuNP–Aβ42 
aggregation, eliciting no visible precipitation and generating International Journal of Nanomedicine 2011:6
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Figure 2 Confirmation of Aβ42 conjugation to AuNP and induction of AuNP–Aβ42 precipitates by Aβ42 aggregation. A) Verification of biotin–Aβ42 conjugation to 
streptavidin-AuNP by dot blot analysis. B) After 48 hours incubation, visible AuNP–Aβ42 precipitates formed in the bottom of the tubes and the supernatant became clear; 
no precipitate was observed in the AuNP control. C) Optical density of supernatant as a quantitative indicator of AuNP–Aβ42 precipitation (Paired t-test, ***P , 0.0001). 
D) ThT binding assay to measure and quantify Aβ42 aggregation, reflected by significantly increased ThT binding in AuNP–Aβ42 (**P , 0.005).
Abbreviations: Aβ42, amyloid β42; AuNP, gold nanoparticle; ThT, thioflavin T.
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a completely different color in the supernatant compared 
with AuNP–Aβ42 (Figure 4A). TTR rescued the decrease in 
optical density and increase in ThT binding in AuNP–Aβ42 
by inhibiting Aβ42 aggregation (Figure 4B and 4C).
By TEM, the particle arrangement of AuNP–Aβ42 pre-
cipitate was identified, as was its change on TTR inhibition 
of Aβ aggregation. The AuNP–Aβ42 preparation was the 
same as in the previous experiment. The same concentrations 
and volumes of AuNP, free Aβ42 (50 µmol/L, Aβ42 without 
biotin, American Peptide, Sunnyvale, CA), TTR (3 µmol/L, 
Sigma) were used for each set. Unconjugated AuNP did not 
cluster and dispersed homogeneously, whereas AuNP–Aβ42 
assembled and clustered, distributing itself heterogeneously 
(Figure 5A). Particle distances fell significantly in AuNP–
Aβ42 aggregates, compared with AuNP without Aβ42 conju-
gation (P , 0.001) (Figure 5A and 5B). Small gaps between 
particles in AuNP–Aβ42 were possible spaces for conjugated 
Aβ42 to aggregate. Incubation of AuNP–Aβ42 with addi-
tional free Aβ42 led to the same pattern of precipitation as 
with 300 µmol/L biotin–Aβ42 in Figure 3, which formed 
floating dark purple granules (Supplementary Figure 2). The 
distances between particles were greater than in AuNP–Aβ42 
aggregates but shorter than the AuNP control, and the 
background appeared dark and irregular, possibly reflecting 
the aggregation of free Aβ42. Incubation of AuNP–Aβ42 
with TTR for 48 hours did not cause precipitation or cluster-
ing of AuNP–Aβ42, and the particles were distributed evenly, 
as in the control, due to the inhibition of aggregation by TTR 
(Figure 5A and 5B, Supplementary Figure 2). There was no 
difference from the AuNP control and a significant increase 
compared with AuNP–Aβ42 (P , 0.001) with regard to 
particle distance, and background staining did not develop. 
TTR had no direct effect on AuNPs when they were added 
with TTR (Supplementary Figure 2). These results suggest 
that this AuNP–Aβ42 system is a potential method for screen-
ing candidates of Aβ42 aggregation inhibitors. Visualizing 
AuNP–Aβ42 precipitation would be a tremendous advantage 
in validating inhibitor activities and specificities.
Differential aggregation patterns  
of AuNP–Aβ42 in sera from  
normal and AD patients
We hypothesized that this system could be used for blood-
derived samples to differentiate AD patients from normal 
individuals by monitoring AuNP–Aβ42 aggregation. Serum 
(1/20 dilution) from four AD patients and four normal controls International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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was tested. The average ages of control and AD subjects 
were 71 ± 2.00 and 80 ± 3.65 years, respectively. Serum 
TTR levels were also quantified and compared, showing 
1227.25 ± 18.30 in the control and 408.25 ± 75.33 in the AD 
group, respectively. Although it was hard to tell the clear differ-
ences in AuNP–Aβ42 precipitation patterns   (Supplementary 
Figure 3), TEM images showed increased AuNP–Aβ42 
aggregation in AD serum and relatively even distribution 
of particles in the normal controls (Figure 6A and 6B). The 
background developed irregular patterns of protein aggre-
gation in both normal and AD patients. In normal serum, 
AuNP–Aβ42 spread evenly, yet AuNP–Aβ42 in AD serum 
clustered near or above the protein aggregate, reflected by 
the dark background staining. Moreover, Figure 6B shows 
differential patterns of AuNP–Aβ42 aggregation between 
normal and AD   individuals, revealing that the interparticle 
distance was significantly shortened in AD compared with 
normal samples. In AD samples, particles clustered near the 
protein aggregation of dark-stained background, whereas 
homogeneous dispersion was shown in normal subjects.
Discussion
We have demonstrated that the combination of two distinct 
properties – the color of visible precipitates of AuNPs and 
the aggregation-prone nature of Aβ – makes the visualization 
of Aβ aggregation possible. The strong conjugation of Aβ42 
to AuNP by biotin–streptavidin interaction, followed by a 
48-hour incubation in PBS (pH = 7.2), induced aggregation, 
which was detected easily as dark purple precipitation.
Kogan et al reported that 10 nm β sheet breaker (PEP)-
conjugated AuNP recognized and bound the hydrophobic 
pocket of Aβ42 and formed small black precipitates after 
168 hours at 37°C.17 Their purpose in inducing hydrophobic 
aggregation between AuNP–PEP and Aβ was to use AuNPs 
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to mediate the delivery of irradiation to Aβ aggregates, 
demonstrating the dissolution of Aβ precipitate and the reap-
pearance of the red AuNP solution by irradiation. However, 
the precipitate was rarely visible, and 168 hours is a long 
period to wait to induce protein aggregation.
Thus, we conjugated full-length Aβ42 directly to AuNP 
through strong interactions of biotin–streptavidin. This spe-
cific conjugation fastened aggregation and precipitation only 
after 48 hours at RT, allowing us to quantify and compare 
AuNP–Aβ42 precipitates. Protein aggregation and fibril 
formation have nucleation-dependent kinetics; thus, Aβ42 
nucleation appears to be the rate-limiting step of aggregation 
and fibrillation. Nanoparticles may initiate protein nucleation 
and reduce nucleation lag time.15
Our results in Figure 2 show that the attachment of Aβ42 
to nanoparticles induced aggregation in a relatively short 
time (48 hours), compared with 168 hours in Kogan et al’s 
experiments. Also, it is noted that the appearance of 
AuNP–Aβ42 precipitates induced by full-length Aβ42 
aggregation in our study differed from the hydrophobic 
incorporation of small-fragment Aβ42 to full-length Aβ42. 
Factors such as size of nanoparticle, types, and length of 
Aβ and conjugation method might affect the appearance 
of this precipitate.
This visible AuNP–Aβ42 precipitate system is useful in 
screening and validating possible drug targets and diagnostic 
approaches. TTR, a well known Aβ42 aggregation inhibi-
tor, had no direct influence on AuNP itself (Supplementary 
Figure 2), but it blocked AuNP–Aβ42 precipitation by inhib-
iting Aβ42 aggregation (Figure 4). The possible explanation 
for this phenomenon is that TTR binds to Aβ42 and blocks 
the initial nucleation of Aβ42 aggregation, which prohibits 
further processing. We incubated AuNP–Aβ42 and TTR for 
up to 168 hours and did not observe any difference.
The TEM analysis in Figure 5 details the structure and 
interparticle distances of AuNP–Aβ42 precipitates and TTR 
activity. AuNP–Aβ42+TTR affected a particle distance and 
distribution that were similar to those in AuNP control, but 
AuNP–Aβ42 alone clustered in an irregular pattern. As dis-
cussed, AuNP–Aβ42+free Aβ42 clustered and precipitated 
in a pattern that differed from AuNP–Aβ42. Additional 
free Aβ42 lengthened the particle distance compared with 
AuNP–Aβ42 aggregates but remained shorter than the AuNP 
control. Also, the addition of free Aβ42 to AuNP–Aβ42 
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(AuNP–Aβ42+free Aβ42) induced a dark background of 
protein that did not appear in AuNP–Aβ42 (Figure 5A). 
This result might have been caused by the intervention of 
free Aβ42 into AuNP–Aβ42 aggregates during precipitation, 
and the irregular background staining reflects Aβ42 aggrega-
tion between AuNP–Aβ42 and free Aβ42. Also, based on 
this result, we are reassured that AuNP–Aβ42 precipitate is 
caused by aggregation of “unfree” biotin–Aβ42 but conju-
gated Aβ42 to AuNP. We might be able to use these distinct 
characteristics of AuNP–Aβ42 precipitates in the presence of 
free Aβ42 to detect and quantify free Aβ42 by adjusting the 
proportion of conjugated and free Aβ42 in future studies. At 
certain concentration ratios – possibly a lower biotin–Aβ42 
concentration than what is used to saturate AuNP surfaces 
(50 µmol/L) – free Aβ42 might lead to aggregation and precipi-
tation that are proportional to the free Aβ42 concentration.
Levels of protein aggregates, appearing as background 
staining by TEM, peaked in blood-derived serum samples 
(Figure 6). High concentrations of diverse proteins in serum 
and the nonspecific intercalation of AuNP–Aβ42 into serum 
protein aggregates meant that it was not possible to see a 
clear difference in AuNP–Aβ42 precipitates between normal 
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Abbreviations: Aβ42, amyloid β42; AuNP, gold nanoparticle; TeM, transmission electron microscopy; TTr, transtyretin.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and AD-derived sera, yet TEM analysis clearly showed 
differential patterns of particle distance and aggregation. 
Compared with normal samples, AD serum that was incu-
bated with AuNP–Aβ42 developed AuNP–Aβ42 clusters 
with significantly short particle distances; most aggregates 
were concentrated in the dark protein aggregation background 
stain. This result might be explained by several mechanisms. 
First, the concentration of Aβ42 aggregation inhibitor might be 
lower in AD blood compared with normal subjects. As shown 
in Figure 4, TTR is a known active Aβ42 aggregation inhibitor 
that exists in low concentrations in CSF of AD patients.12 We 
confirmed the concentration of TTR in blood-derived serum, 
quantified by ELISA, and demonstrated significantly lower 
concentrations in AD subjects compared with the normal 
group. Besides TTR, the possibility of the existence of AD-
related changes of other Aβ binding proteins could not be 
excluded. The potential role of metal ions has been reported 
in Aβ aggregation and AD pathogenesis. Metal ions, such as 
copper and zinc, bind to Aβ42, and their concentrations are 
susceptible to change during AD pathogenesis.21 Metal ions, 
especially copper and zinc, bind and induce Aβ42 aggregation, 
and their concentration in blood might change during the 
pathogenic process and influence Aβ42 aggregation.22,23 
Other factors that might govern Aβ42 aggregation should 
be considered, including biological lipids, which have been 
reported to generate toxic Aβ42 protofibrils.24
Conclusion
We visualized Aβ42 aggregation through the conjugation 
of Aβ42 to AuNPs. AuNP–Aβ42 precipitate was quantified 
by optical density measurements of AuNP supernatant and 
ThT binding assay. With this method, an Aβ42 aggregation 
inhibitor screen was performed and successfully validated the 
effect of TTR against AuNP–Aβ42 aggregation. Our TEM 
analysis supported these results and further differentiated 
between aggregation patterns of AuNP–Aβ42 in AD blood 
and normal controls. These findings establish a valuable 
screening system for Aβ aggregation regulators and poten-
tiate the development of diagnostic and prognostic tools 
for neurodegenerative diseases in which abnormal protein 
aggregation is the critical step in their pathogenesis.
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Figure S1 Time-dependent aggregation and precipitation pattern of AuNP–Aβ42.
Abbreviations: Aβ, amyloid β; Aβ42, amyloid β42; AuNP, gold nanoparticle; ThT, thioflavin T.
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Figure S2 Precipitation pattern of AuNP–Aβ42 with or without TTr or free Aβ42. 
Images were taken before the TeM analysis in Figure 5.
Abbreviations: Aβ42, amyloid β42; AuNP, gold nanoparticle; TeM, transmission 
electron microscopy; TTr, transtyretin.
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Figure S3 Precipitation pattern of AuNP–Aβ42 incubated with sera from normal 
and AD patients. Images were taken before TeM analysis in Figure 6.
Abbreviations:  AD,  Alzheimer’s  disease;  Aβ42,  amyloid  β42;  AuNP,  gold 
nanoparticle; TeM, transmission electron microscopy.